MedTrace Logo

Mass Balance Study of AT-527 in Healthy Adult Male Subjects (R07496998)

NCT05004415 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2022-02-25

No results posted yet for this study

Summary

Mass balance study of AT-527 in Healthy Male Subjects.

Conditions

  • Healthy Volunteer Study

Interventions

DRUG

AT-527 (R07496998)

Study participants will receive a single radiolabeled dose of 550 mg AT-527.

Sponsors & Collaborators

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
19 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-07-28
Primary Completion
2021-08-12
Completion
2021-08-12
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05004415 on ClinicalTrials.gov